Terlipressin

Generic Name: Terlipressin

Brand Names: Terlivaz

Drug Type: Biotech

CAS Number: 14636-12-5

Unique Ingredient Identifier: 7Z5X49W53P

Background: Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in various shock states and conditions with diminished vasomotor tone. It was also studied in hepatorenal syndrome (HRS) and variceal bleeding. The drug was first approved by the FDA in September 2022.

Indication: Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.

Associated Conditions: Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension

Clinical Trials

Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation

Not Applicable

Recruiting

Conditions: Kidney Transplant
Delayed Graft Function
Intraoperative Hypotension

Interventions: Drug: terlipressin

First Posted Date: 2025-03-04

Last Posted Date: 2025-03-20

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 150

Registration Number: NCT06855758

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, China

Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed

Phase 2

Not yet recruiting

Conditions: Acute on Chronic Liver Failure

Interventions: Drug: Terlipressin Injectable Product

First Posted Date: 2025-02-07

Last Posted Date: 2025-02-07

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 60

Registration Number: NCT06815770

Locations: 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock

Not Applicable

Not yet recruiting

Conditions: Acute on Chronic Liver Failure

Interventions: Drug: Terlipressin
Drug: Norephrine

First Posted Date: 2024-08-16

Last Posted Date: 2024-08-16

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Target Recruit Count: 126

Registration Number: NCT06556472

Locations: 🇮🇳
Institute of Liver & Biliary Sciences (ILBS), New Delhi, Delhi, India

Endothelin Receptor Antagonism with Ambrisentan to Treat Hepatorenal Syndrome

Phase 2

Recruiting

Conditions: Acute Kidney Injury
Hepatorenal Syndrome
Liver Cirrhosis
Ascites Hepatic

Interventions: Drug: Terlipressin
Drug: Ambrisentan

First Posted Date: 2024-02-13

Last Posted Date: 2025-01-30

Lead Sponsor: Noorik Biopharmaceuticals AG

Target Recruit Count: 54

Registration Number: NCT06256432

Locations: 🇮🇳
Asian Institute of Gastroenterology (AIG), Hyderabad, Telangana, India
🇮🇳
All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳
Aster CMI Hospital, Bangalore, Karnataka, India

and more 3 locations

Terlipressin in Combined Hepatorenal Syndrome in Patients With Signs of Chronic Renal Disease

Completed

Conditions: Chronic Kidney Diseases
Liver Cirrhosis
Hepato-Renal Syndrome

Interventions: Drug: terlipressin or noradrenalin plus albumin

First Posted Date: 2023-12-08

Last Posted Date: 2024-12-09

Lead Sponsor: University Hospital Freiburg

Target Recruit Count: 490

Registration Number: NCT06161766

Locations: 🇩🇪
University Medical Center Freiburg, Freiburg, Germany
🇩🇪
University Medical center Jena, Jena, Germany
🇩🇪
University Medical Center Mainz, Mainz, Germany

and more 1 locations

Effect of Terlipressin on the Incidence of Early Postoperative Acute Kidney Injury in Liver Transplantation Patients

Phase 4

Recruiting

Conditions: Liver Transplant; Complications
Acute Kidney Injury

Interventions: Drug: normal saline
Drug: Terlipressin

First Posted Date: 2023-10-31

Last Posted Date: 2023-10-31

Lead Sponsor: Beijing Tsinghua Chang Gung Hospital

Target Recruit Count: 104

Registration Number: NCT06108362

Locations: 🇨🇳
Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing, China

Efficacy of Continuous Terlipressin Therapy After Endoscopic Variceal Ligation

Phase 3

Not yet recruiting

Conditions: Variceal Hemorrhage

Interventions: Other: 0.9% normal saline (NS)
Drug: Terlipressin

First Posted Date: 2023-09-07

Last Posted Date: 2023-09-07

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 165

Registration Number: NCT06027970

Locations: 🇮🇳
Department of Internal Medicine, Post Graduate Institute of Medical Education and Research,, Chandigarh, India

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

Phase 2

Recruiting

Conditions: Hepatorenal Syndrome
Acute Kidney Injury

Interventions: Drug: R2R01
Drug: Terlipressin

First Posted Date: 2023-05-25

Last Posted Date: 2023-10-03

Lead Sponsor: River 2 Renal Corp.

Target Recruit Count: 95

Registration Number: NCT05875948

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Baylor Scott and White All Saints Medical Center, Fort Worth, Texas, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States

and more 4 locations